On 12 October, Sprint Corporation (NYSE:S) shares moved up 0.67% and was closed at $4.50. S EPS growth in last 5 year was -73.48%. Sprint Corporation (NYSE:S) year to date (YTD) performance is 8.43%.
On 9 October, .com, Inc. (NASDAQ:JD) announced the launch of German Mall, the latest addition to JD.com’s growing suite of country-focused curated channels that showcase a range of authentic, imported products from leading global brands.
CYS Investments, Inc. (NYSE:CYS) ended the last trading day at $7.84. Company weekly volatility is calculated as 1.56% and price to cash ratio as 24.65. CYS Investments, Inc. (NYSE:CYS) showed a weekly performance of 2.75%.
CYS Investments, Inc. (NYSE: CYS) announced that it will host a conference call at 9:00 AM Eastern Time on Thursday, October 22, 2015, to discuss its financial results for the quarter ended September 30, 2015.
On 12 October, Forum Energy Technologies, Inc. (NYSE:FET) shares decreased -7.13% and was closed at $13.93. FET EPS growth in last 5 year was 50.10%. Forum Energy Technologies, Inc. (NYSE:FET) year to date (YTD) performance is -32.80%.
Forum Energy Technologies, Inc. (NYSE:FET) announced that it will host its third quarter 2015 earnings conference call at 8:00 AM CDT on Friday, October 23, 2015. Forum will issue a press release regarding its third quarter 2015 earnings prior to the conference call.
Ocata Therapeutics, Inc. (NASDAQ:OCAT) shares decreased -5.53% in last trading session and ended the day at $4.44. OCAT Gross Margin is 50.00% and its has a return on assets of -189.10%. Ocata Therapeutics, Inc. (NASDAQ:OCAT) quarterly performance is -14.12%.
Ocata Therapeutics, Inc. (NASDAQ:OCAT), reported in Regenerative Medicine that it has successfully used its proprietary hemangio-derived mesenchymal cell (HMCTM) technology to treat dogs with canine anal furunculosis (CAF), which shares many features with Crohn’s disease. This study provides the first evidence of the safety and therapeutic potential of human pluripotent stem cell-derived mesenchymal stem cells in a large animal model,” said Robert Lanza, M.D., Chief Scientific Officer of Ocata. “Canines have a physiology and sophisticated immune system that closely resembles that of humans, and canines are the only species that naturally develop symptoms and pathology similar to human fistulizing Crohn’s disease, including recurrent fistula activity, a difficult-to-treat manifestation of this chronic inflammatory bowel disorder.
NVIDIA Corporation (NASDAQ:NVDA) caters to the Technology space. It has a net profit margin of 11.00% and weekly performance is 3.66%. On the last day of trading company shares ended up at $26.35. NVIDIA Corporation (NASDAQ:NVDA) distance from 50-day simple moving average (SMA50) is 15.04%.
NVIDIA Corporation (NASDAQ:NVDA)’s Jen-Hsun Huang has been named the 29th best-performing CEO in the world, in a new study in the November issue of Harvard Business Review.
The top three CEOs in the study – which is based on an 80-20 weighting between the company’s financial performance and its performance on environmental, social and governance criteria – are Lars Rebien Sorensen, of Danish pharmaceutical company Novo Nordisk; John Chambers, of Cisco; and Pablo Isla, of Spanish retailer Inditex. Rounding out the top five are Elmar Degenhart, of German autoparts-maker Continental, and Martin Sorrell, of WPP, the UK consumer-services group.
Leave a Reply